“FDA Extends Review of Ascendis Pharma’s Groundbreaking TransCon CNP Therapy for Children with Achondroplasia”

Ascendis Pharma’s therapy for children with dwarfism, known as TransCon CNP (navepegritide), is currently under extended review by the U.S. Food and Drug Administration (FDA). This therapy targets achondroplasia, the most common form of dwarfism caused by a rare genetic disorder. The FDA delayed its decision past the original November 30, 2025, deadline, providing additional time to assess the therapy’s safety and efficacy before potential approval.

TransCon CNP is a once-weekly injectable prodrug designed to provide continuous exposure to C-type natriuretic peptide (CNP), which plays a role in regulating bone growth. Clinical trials, including the pivotal ApproaCH trial—a randomized, double-blind, placebo-controlled study involving 84 children aged 2 to 11 with achondroplasia—have demonstrated that children treated with TransCon CNP showed significantly higher annualized growth velocity compared to placebo (about 5.89 cm/year versus 4.41 cm/year at 52 weeks). In addition to increased growth rates, treated children experienced improvements in body proportionality and other growth parameters without serious adverse events or acceleration in bone age relative to chronological age. The treatment was generally well tolerated, with mild injection site reactions reported at low frequency and no cases of symptomatic hypotension or fractures related to the drug.​

Experts not involved in the trials have acknowledged the potential of TransCon CNP as an important advancement in managing achondroplasia. Aimee Shu, MD, Chief Medical Officer at Ascendis Pharma, highlighted that benefits extend beyond linear growth to reducing health burdens related to the condition, such as leg bowing and impaired mobility. The therapy could potentially reduce future complications including pain and the need for surgery, improving overall quality of life for affected children. However, medical professionals note that longer-term data and post-approval surveillance will be crucial to fully understand the long-term safety and functional outcomes.​

Achondroplasia results from mutations affecting FGFR3 gene function, which inhibits bone growth. TransCon CNP works by continuously delivering active CNP to skeletal tissues, counteracting the pathogenic signals that limit height. The treatment’s once-weekly dosing aims to offer convenience alongside clinical effectiveness. The FDA’s extended review underscores the regulatory complexity of balancing novel therapies’ benefits against potential risks, especially in pediatric populations with chronic conditions. While TransCon CNP’s data are promising, there remain questions about how broadly the treatment will impact all patients and if it will substantially alter the disease’s natural course in adulthood.

For parents and caregivers, the therapy represents a hopeful option for improving height and physical function in children with achondroplasia, provided they consult with healthcare professionals to weigh potential benefits and risks. As the FDA completes its assessment, families and clinicians await a decision that could change the standard of care for this rare genetic disorder.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: